Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) posted its earnings results on Thursday, August 7th. The company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.49), Zacks reports.
Avalo Therapeutics Stock Performance
AVTX stock traded down $0.12 during trading on Thursday, reaching $8.95. The stock had a trading volume of 944,343 shares, compared to its average volume of 321,195. Avalo Therapeutics has a 1-year low of $3.39 and a 1-year high of $16.00. The firm has a fifty day moving average price of $5.97 and a 200 day moving average price of $6.06.
Hedge Funds Weigh In On Avalo Therapeutics
A hedge fund recently raised its stake in Avalo Therapeutics stock. Geode Capital Management LLC grew its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 2.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 110,460 shares of the company's stock after purchasing an additional 2,648 shares during the quarter. Geode Capital Management LLC owned approximately 1.02% of Avalo Therapeutics worth $552,000 as of its most recent filing with the SEC. 87.06% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, HC Wainwright upgraded shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price objective on the stock in a report on Monday, June 2nd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $30.00.
Check Out Our Latest Stock Report on Avalo Therapeutics
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Stories
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
